Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic.
作者信息
Brown Joshua D
机构信息
Center for Drug Evaluation & Safety, Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, USA.
出版信息
Res Social Adm Pharm. 2021 Jan;17(1):2053. doi: 10.1016/j.sapharm.2020.03.020. Epub 2020 Mar 31.
Abstract
摘要
相似文献
1
Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic.大麻二酚可预防新型冠状病毒和新冠肺炎？毫无根据的说法与疫情期间药物的潜在风险
Res Social Adm Pharm. 2021 Jan;17(1):2053. doi: 10.1016/j.sapharm.2020.03.020. Epub 2020 Mar 31.
2
A day of relief and hope.充满慰藉与希望的一天。
Am J Health Syst Pharm. 2021 Jun 7;78(12):1126-1127. doi: 10.1093/ajhp/zxab115.
3
Causes and treatment of Covid-19: Myths vs Facts.Covid-19 的病因与治疗：真相与误区。
Pak J Pharm Sci. 2020 Jul;33(4):1731-1734.
4
Pharmacist-Led Chronic Care Management for Medically Underserved Rural Populations in Florida During the COVID-19 Pandemic.在 COVID-19 大流行期间，佛罗里达州为医疗资源不足的农村人群提供药师主导的慢性病管理。
Prev Chronic Dis. 2020 Jul 30;17:E74. doi: 10.5888/pcd17.200265.
5
A rational approach to COVID-19.对 COVID-19 的理性应对。
Hum Genomics. 2020 Dec 22;14(1):47. doi: 10.1186/s40246-020-00300-5.
6
Chinese pharmacists' rapid response to the COVID-19 outbreak.中国药剂师对新冠疫情的快速反应。
Am J Health Syst Pharm. 2020 Jul 7;77(14):1096-1097. doi: 10.1093/ajhp/zxaa120.
7
SARS-Cov-2 in peritoneal fluid: an important finding in the Covid-19 pandemic.SARS-CoV-2 在腹腔液中的存在：新冠疫情中的一个重要发现。
Br J Surg. 2020 Sep;107(10):e376. doi: 10.1002/bjs.11816. Epub 2020 Jul 20.
8
The Potential Transmission of SARS-CoV-2 from Patients with Negative RT-PCR Swab Tests to Others: Two Related Clusters of COVID-19 Outbreak.从 RT-PCR 咽拭子检测阴性的患者向他人传播 SARS-CoV-2 的可能性：两起新冠肺炎暴发的聚集性疫情。
Jpn J Infect Dis. 2020 Nov 24;73(6):399-403. doi: 10.7883/yoken.JJID.2020.165. Epub 2020 May 29.
9
Pharmacists' Preparedness to Patients Education at the Time of Pandemic-A Cross-Sectional Study with an Example of SARS-CoV-2 Outbreak in Poland.药剂师在大流行期间对患者教育的准备情况——以 SARS-CoV-2 在波兰爆发为例的横断面研究。
Int J Environ Res Public Health. 2020 Sep 12;17(18):6659. doi: 10.3390/ijerph17186659.
10
Recommendations and guidance for providing pharmaceutical care services during COVID-19 pandemic: A China perspective.在 COVID-19 大流行期间提供药学服务的建议和指导：中国视角。
Res Social Adm Pharm. 2021 Jan;17(1):1819-1824. doi: 10.1016/j.sapharm.2020.03.012. Epub 2020 Mar 26.
引用本文的文献
1
Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review.载有大麻二酚的托珠单抗包覆固体脂质纳米粒作为治疗 COVID-19 的新型药物传递策略：综述。
Front Immunol. 2023 Mar 22;14:1147991. doi: 10.3389/fimmu.2023.1147991. eCollection 2023.
2
Detecting Tweets Containing Cannabidiol-Related COVID-19 Misinformation Using Transformer Language Models and Warning Letters From Food and Drug Administration: Content Analysis and Identification.使用Transformer语言模型和美国食品药品监督管理局的警告信检测包含与大麻二酚相关的COVID-19错误信息的推文：内容分析与识别
JMIR Infodemiology. 2023 Jan 23;3:e38390. doi: 10.2196/38390. eCollection 2023.
3
Will Cannabis or Cannabinoids Protect You from SARS-CoV-2 Infection or Treat COVID-19?大麻或大麻素能保护你免受SARS-CoV-2感染或治疗新冠肺炎吗？
Med Cannabis Cannabinoids. 2022 Feb 25;5(1):32-35. doi: 10.1159/000522472. eCollection 2022.
4
Israeli news media coverage of COVID-19 and use of cannabis and tobacco: A case study of inconsistent risk communication.以色列新冠疫情新闻媒体报道与大麻和烟草使用：风险沟通不一致的案例研究。
Int J Drug Policy. 2022 May;103:103648. doi: 10.1016/j.drugpo.2022.103648. Epub 2022 Mar 7.
5
Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy.大麻二酚和萜烯配方降低 SARS-CoV-2 感染力——一种治疗策略。
Front Immunol. 2022 Feb 15;13:841459. doi: 10.3389/fimmu.2022.841459. eCollection 2022.
6
Laboratory and clinical research on COVID-19: focus on non-lung organs.关于新型冠状病毒肺炎的实验室及临床研究：聚焦于非肺部器官
Cond Med. 2020 Oct;3(5):239-240.
7
Cannabinoids and Inflammations of the Gut-Lung-Skin Barrier.大麻素与肠-肺-皮肤屏障炎症
J Pers Med. 2021 May 31;11(6):494. doi: 10.3390/jpm11060494.
8
Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19.将大麻二酚用作COVID-19辅助药物的机遇、挑战与陷阱
Int J Mol Sci. 2021 Feb 17;22(4):1986. doi: 10.3390/ijms22041986.
9
The Potential Role of Super Spread Events in SARS-COV-2 Pandemic; a Narrative Review.超级传播事件在新冠疫情中的潜在作用；一篇叙述性综述。
Arch Acad Emerg Med. 2020 Sep 21;8(1):e74. eCollection 2020.
10
The Prevalence of Underlying Diseases and Comorbidities in COVID-19 Patients; an Updated Systematic Review and Meta-analysis.新冠病毒肺炎患者基础疾病和合并症的患病率；一项更新的系统评价和荟萃分析
Arch Acad Emerg Med. 2020 Sep 12;8(1):e72. eCollection 2020.
本文引用的文献
1
Immune Responses Regulated by Cannabidiol.大麻二酚调节的免疫反应。
Cannabis Cannabinoid Res. 2020 Feb 27;5(1):12-31. doi: 10.1089/can.2018.0073. eCollection 2020 Mar 1.
2
Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug-Drug Interactions.由于药物相互作用导致的四氢大麻酚（THC）潜在药物不良事件。
J Clin Med. 2020 Mar 27;9(4):919. doi: 10.3390/jcm9040919.
3
Antihypertensive drugs and risk of COVID-19?抗高血压药物与新型冠状病毒肺炎风险？
Lancet Respir Med. 2020 May;8(5):e28. doi: 10.1016/S2213-2600(20)30158-2. Epub 2020 Mar 26.
4
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?高血压和糖尿病患者感染新型冠状病毒肺炎（COVID-19）的风险会增加吗？
Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11.
5
Community pharmacist in public health emergencies: Quick to action against the coronavirus 2019-nCoV outbreak.社区药剂师在公共卫生突发事件中的作用：迅速应对 2019 年新型冠状病毒疫情。
Res Social Adm Pharm. 2020 Apr;16(4):583-586. doi: 10.1016/j.sapharm.2020.02.003. Epub 2020 Feb 12.
6
Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use.使用医用和消费级大麻二酚（CBD）时潜在的药物不良事件和药物相互作用。
J Clin Med. 2019 Jul 8;8(7):989. doi: 10.3390/jcm8070989.
Zotero 插件